Diplomat Pharmacy,Inc. (NYSE:DPLO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February22, 2019, Diplomat Pharmacy,Inc. (the “Company”) issued a press release (the “Press Release”) publicly announcing preliminary financial results for the year ended December31, 2018 and withdrawing its previously issued preliminary 2019 full-year outlook. A copy of the Press Release is attached hereto as Exhibit99.1, which is incorporated herein by reference. The information in this Item 2.02 and the attached exhibit shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On February22, 2019, the Company issued the Press Release further announcing that it had recently determined the need to record a non-cash impairment charge related to the pharmacy benefit management (“PBM”) business equal to a significant portion of the PBM business’s goodwill and definite-lived intangible assets. The Company identified the need to record the non-cash impairment charge during the course of its preparation of its financial statements for inclusion in the Form10-K for the fiscal year ended December31, 2018 (the “2018 Form10-K”) as a result of reduced financial forecasts for the PBM business. The Company’s Press Release announced that as a result of the aforementioned, the Company and its auditors need additional time to finalize the level of impairment and allocation between goodwill and definite-lived intangible assets, and that as a result the Company was delaying the release of its fourth quarter and full year 2018 earnings release, rescheduling its earnings call to March15, 2019 and delaying the filing of the 2018 Form10-K. A copy of the Press Release is attached hereto as Exhibit99.1, which is incorporated herein by reference.
The information in this Item 7.01 and the attached exhibit shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit99.1 |
Company news release dated February22, 2019. |
Diplomat Pharmacy, Inc. Exhibit
EX-99.1 2 a19-5253_1ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE: CONTACT: Feb. 22,…
To view the full exhibit click here
About Diplomat Pharmacy,Inc. (NYSE:DPLO)
Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Company operates through specialty pharmacy services segment. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. Its specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
